查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1608113

吸入药品市场：按产品、按应用划分 - 2025-2030 年全球预测

Inhalable Drugs Market by Product (Aerosol, Dry Powder Formulation, Spray), Application (Non-Respiratory Diseases, Respiratory Diseases) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

据预测，2023年吸入药品市值为350.1亿美元，预计到2024年将达到376亿美元，复合年增长率为6.05%，到2030年将达到528.4亿美元。

吸入药物是一种设计用于透过呼吸系统输送的製剂，具有快速吸收和针对气喘和慢性阻塞性肺病等呼吸系统疾病的针对性作用的潜在益处。对吸入药物的需求不断增长，是因为它们在慢性呼吸道疾病的治疗中发挥着重要作用，而且此类疾病在全球范围内的患病率不断上升。其应用范围广泛，包括全身性疾病治疗、疼痛管理，甚至疫苗等药物传递（可透过吸入非侵入性给药），强化了这种需求。最终用户包括医院、诊所和家庭护理机构，反映出这些药物的广泛采用。市场成长受到呼吸系统疾病发病率上升、给药系统技术进步以及对高效和患者友好的治疗方案的需求等因素的显着影响。市场区隔的机会在于新兴市场的扩张、智慧吸入器等自适应技术，以及个人化医疗和生技药品创新带来的慢性阻塞性肺病和气喘领域的成长。为了充分利用这一潜力，相关人员应专注于产能扩张、监管合规性以及产品开发和分销的策略伙伴关係。儘管前景广阔，但该市场仍面临监管挑战、潜在副作用和高开发成本等限制。来自口服药物的竞争和正在进行的替代疗法研究也增加了这些挑战。需要创新的领域包括改进吸入器设计以提高剂量准确性、提高生物有效性的药物处方以及整合数位健康技术以监测和提高患者依从性。透过了解使用者体验并解决现有的设计缺陷，获得对未满足的市场需求的可行见解。总体而言，吸入药品市场展现出动态的成长潜力，技术和创新被定位为关键驱动力，同时克服严格的监管和市场渗透挑战对于未来的成功仍然很重要。

主要市场统计
基准年[2023] 350.1亿美元
预计年份 [2024] 376亿美元
预测年份 [2030] 528.4亿美元
复合年增长率（%） 6.05%

市场动态：揭示快速发展的吸入药品市场的关键市场洞察

供需的动态交互作用正在改变吸入药品市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 慢性阻塞性肺病和气喘等呼吸系统疾病的盛行率增加
    • 增加医疗基础设施并提高患者意识
    • 帕金森氏症等非呼吸系统疾病迅速增加
  • 市场限制因素
    • 关于吸入药物核准的严格规定
  • 市场机会
    • 易于给药的吸入药物的快速开发
    • 活性化的运动将目前的不可吸入分子改良为可吸入分子，以改善药物输送。
  • 市场挑战
    • 不受监管的替代疗法的可用性

波特五力：驾驭吸入药物市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解吸入药品市场的外部影响

外部宏观环境因素在塑造吸入药品市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解吸入药物市场的竞争格局

对吸入药品市场的详细市场占有率分析可以对供应商的业绩进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的见解，以应对日益激烈的竞争。

FPNV 定位矩阵吸入药品市场供应商的绩效评估

FPNV 定位矩阵是评估吸入药品市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议为吸入药物市场的成功指明了道路

对于旨在加强其在全球市场的影响力的公司来说，吸入药品市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 慢性阻塞性肺病和气喘等呼吸系统疾病的发生率增加
      • 加强医疗基础设施并意识提升
      • 帕金森氏症等非呼吸系统疾病迅速增加
    • 抑制因素
      • 吸入药物核准的严格规定
    • 机会
      • 吸入药物的快速开发以简化给药
      • 将目前的不可吸入分子重新配製为可吸入分子以改善药物输送的运动日益盛行。
    • 任务
      • 不受监管的替代疗法的可用性
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 吸入药物市场：副产品

  • 气雾剂
  • 干粉配方
  • 喷

第七章 吸入药物市场：依应用分类

  • 非呼吸系统疾病
  • 呼吸系统疾病

第八章美洲吸入药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太吸入药品市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲吸入药品市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争场景分析
  • 战略分析和建议

公司名单

  • Aptargroup, Inc.
  • AstraZeneca PLC
  • Avalyn Pharma, Inc.
  • Boehringer Ingelheim International GmbH
  • Cipla Inc.
  • GEA Group Aktiengesellschaft
  • Merck & Co., Inc.
  • Novartis AG
  • Orion Corporation
  • Pfizer Inc.
  • PureIMS BV
  • Respira Therapeutics Inc.
  • Sanofi SA
  • Sunovion Pharmaceuticals Inc. by Sumitomo Dainippon Pharma Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-CA17E905E64D

The Inhalable Drugs Market was valued at USD 35.01 billion in 2023, expected to reach USD 37.60 billion in 2024, and is projected to grow at a CAGR of 6.05%, to USD 52.84 billion by 2030.

Inhalable drugs are formulations designed for delivery through the respiratory system, offering potential advantages in rapid absorption and targeted action in respiratory conditions like asthma and COPD. The growing necessity for inhalable drugs stems from their critical role in managing chronic respiratory diseases and the increasing prevalence of such conditions globally. This necessity is bolstered by their applications, which span administering medication for systemic disease treatments, pain management, and even vaccines where inhalation offers non-invasive administration. End-users include hospitals, clinics, and home care settings, reflecting the broad adoption of these drugs. Market growth is heavily influenced by factors like rising respiratory disease rates, technological advancements in drug delivery systems, and demand for efficient, patient-friendly treatment options. Opportunities lie in expanding markets in developing regions, adaptive technologies like smart inhalers, and growth in COPD and asthma segments, driven by innovation in personalized medicine and biologics. To tap into these potentials, stakeholders should focus on expanding production capabilities, regulatory compliance, and strategic partnerships for product development and distribution. Despite the promising outlook, the market faces limitations such as regulatory challenges, potential side effects; and high development costs. Competition from oral medications and ongoing research in alternative therapies add to these challenges. Areas ripe for innovation include enhancing inhaler design for better dose accuracy, formulating drugs with improved bioavailability, and integration of digital health technologies to monitor and improve patient compliance. Understanding user experiences and addressing existing design drawbacks can provide actionable insights into unmet market needs. Overall, the inhalable drugs market shows dynamic growth potential, with technology and innovation positioned as key drivers while overcoming stringent regulations and market penetration challenges remain important for future success.

KEY MARKET STATISTICS
Base Year [2023] USD 35.01 billion
Estimated Year [2024] USD 37.60 billion
Forecast Year [2030] USD 52.84 billion
CAGR (%) 6.05%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Inhalable Drugs Market

The Inhalable Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidence of respiratory diseases such as chronic obstructive pulmonary diseases and asthma
    • Increasing healthcare infrastructure and rising awareness among patients
    • Surge in the number of non-respiratory diseases such as Parkinson's disease
  • Market Restraints
    • Strict regulations for the approval of inhalable drugs
  • Market Opportunities
    • Surge in development of inhalable drugs for ease of administration
    • Emerging reformulation of current non-inhaled molecules into inhaled molecules for improved drug delivery
  • Market Challenges
    • Availability of unregulated and alternate therapy

Porter's Five Forces: A Strategic Tool for Navigating the Inhalable Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Inhalable Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Inhalable Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Inhalable Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Inhalable Drugs Market

A detailed market share analysis in the Inhalable Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Inhalable Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Inhalable Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Inhalable Drugs Market

A strategic analysis of the Inhalable Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Inhalable Drugs Market, highlighting leading vendors and their innovative profiles. These include Aptargroup, Inc., AstraZeneca PLC, Avalyn Pharma, Inc., Boehringer Ingelheim International GmbH, Cipla Inc., GEA Group Aktiengesellschaft, Merck & Co., Inc., Novartis AG, Orion Corporation, Pfizer Inc., PureIMS B.V., Respira Therapeutics Inc., Sanofi S.A., Sunovion Pharmaceuticals Inc. by Sumitomo Dainippon Pharma Co., Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Inhalable Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Aerosol, Dry Powder Formulation, and Spray.
  • Based on Application, market is studied across Non-Respiratory Diseases and Respiratory Diseases.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidence of respiratory diseases such as chronic obstructive pulmonary diseases and asthma
      • 5.1.1.2. Increasing healthcare infrastructure and rising awareness among patients
      • 5.1.1.3. Surge in the number of non-respiratory diseases such as Parkinson's disease
    • 5.1.2. Restraints
      • 5.1.2.1. Strict regulations for the approval of inhalable drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Surge in development of inhalable drugs for ease of administration
      • 5.1.3.2. Emerging reformulation of current non-inhaled molecules into inhaled molecules for improved drug delivery
    • 5.1.4. Challenges
      • 5.1.4.1. Availability of unregulated and alternate therapy
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Inhalable Drugs Market, by Product

  • 6.1. Introduction
  • 6.2. Aerosol
  • 6.3. Dry Powder Formulation
  • 6.4. Spray

7. Inhalable Drugs Market, by Application

  • 7.1. Introduction
  • 7.2. Non-Respiratory Diseases
  • 7.3. Respiratory Diseases

8. Americas Inhalable Drugs Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Inhalable Drugs Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Inhalable Drugs Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Aptargroup, Inc.
  • 2. AstraZeneca PLC
  • 3. Avalyn Pharma, Inc.
  • 4. Boehringer Ingelheim International GmbH
  • 5. Cipla Inc.
  • 6. GEA Group Aktiengesellschaft
  • 7. Merck & Co., Inc.
  • 8. Novartis AG
  • 9. Orion Corporation
  • 10. Pfizer Inc.
  • 11. PureIMS B.V.
  • 12. Respira Therapeutics Inc.
  • 13. Sanofi S.A.
  • 14. Sunovion Pharmaceuticals Inc. by Sumitomo Dainippon Pharma Co., Ltd.
  • 15. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. INHALABLE DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. INHALABLE DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL INHALABLE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL INHALABLE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL INHALABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS INHALABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS INHALABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES INHALABLE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES INHALABLE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC INHALABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC INHALABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA INHALABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA INHALABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. INHALABLE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. INHALABLE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. INHALABLE DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL INHALABLE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL INHALABLE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL INHALABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. INHALABLE DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL INHALABLE DRUGS MARKET SIZE, BY AEROSOL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL INHALABLE DRUGS MARKET SIZE, BY DRY POWDER FORMULATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL INHALABLE DRUGS MARKET SIZE, BY SPRAY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL INHALABLE DRUGS MARKET SIZE, BY NON-RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL INHALABLE DRUGS MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS INHALABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 19. BRAZIL INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 21. CANADA INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 23. MEXICO INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES INHALABLE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC INHALABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. AUSTRALIA INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. CHINA INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. INDIA INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. INDONESIA INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. JAPAN INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. MALAYSIA INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. PHILIPPINES INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. SINGAPORE INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. SOUTH KOREA INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. TAIWAN INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. THAILAND INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. VIETNAM INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA INHALABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 58. DENMARK INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. EGYPT INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. FINLAND INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. FRANCE INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. GERMANY INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. ISRAEL INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. ITALY INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. NETHERLANDS INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. NIGERIA INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. NORWAY INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. POLAND INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. QATAR INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. RUSSIA INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. SAUDI ARABIA INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH AFRICA INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SPAIN INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. SWEDEN INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. SWITZERLAND INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. TURKEY INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED KINGDOM INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. INHALABLE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 101. INHALABLE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023